SEC Comment Letter for BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497) (BRTX) — Apr 11, 2024

BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497)
Date: April 11, 2024 · CIK: 0001505497 · Accession: 0000000000-24-003948

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-278488

Date

April 11, 2024

Author

Lance Alstodt

Form

UPLOAD

Company

BioRestorative Therapies, Inc. (BRTX) (CIK 0001505497)

Letter

United States securities and exchange commission logo April 11, 2024 Lance Alstodt President and Chief Executive Officer BioRestorative Therapies, Inc. 40 Marcus Drive, Suite One Melville, New York 11747 Re:BioRestorative Therapies, Inc. Registration Statement on Form S-1 Filed April 3, 2024 File No. 333-278488 Dear Lance Alstodt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Ansart at 202-551-4511 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Fred Skolnik

Show Raw Text

United States securities and exchange commission logo
April 11, 2024
Lance Alstodt
President and Chief Executive Officer
BioRestorative Therapies, Inc.
40 Marcus Drive, Suite One
Melville, New York 11747
Re:BioRestorative Therapies, Inc.
Registration Statement on Form S-1
Filed April 3, 2024
File No. 333-278488
Dear Lance Alstodt:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jessica Ansart at 202-551-4511 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       Fred Skolnik

SecProbe.io